What does Nkarta, Inc. do?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for…
What is Nkarta, Inc.'s P/E and P/B ratio?
Nkarta, Inc. has a P/E ratio of -1.1 and a P/B ratio of 0.50.
What is Nkarta, Inc.'s debt-to-equity ratio?
Nkarta, Inc. has a debt-to-equity ratio of 0.30.
How much does Nkarta, Inc. owe compared with what it owns?
Nkarta, Inc. owes $0.27 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Nkarta, Inc.'s Positivity rank?
Nkarta, Inc. is ranked #2,630 of 6,774 companies globally and #897 of 4,000 in United States on PositoAI, with a Positivity Score of 21,307.
Does Nkarta, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Nkarta, Inc..
Where can I read the latest news about Nkarta, Inc.?
Recent headlines about Nkarta, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Nkarta, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Nkarta, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.